JAFRON(300529)2024-04-25 12:05Financial Performance - In Q1 2024, the company achieved revenue of CNY 744.34 million, a year-on-year increase of 30.00%[10] - The net profit attributable to shareholders reached CNY 284.77 million, up 44.90% compared to the previous year[10] - Sales revenue from blood perfusion and adsorption products amounted to CNY 692.01 million, reflecting a significant growth of 85.51% year-on-year[10] - Operating profit increased by 45.80% to CNY 348.72 million, driven by higher sales and cost reduction initiatives[25] - The total profit for the period was CNY 339.93 million, representing a 46.73% increase year-on-year[25] - Revenue from sales of goods and services reached CNY 878,543,970.51, compared to CNY 607,212,411.33, indicating an increase of around 44.5%[42] - Basic earnings per share increased to CNY 0.3512 from CNY 0.2460, representing a growth of approximately 42.7%[42] - The total comprehensive income attributable to the parent company was CNY 284,766,143.10, compared to CNY 196,529,798.71, reflecting an increase of about 44.9%[42] - Net profit after deducting non-recurring gains and losses was ¥270,836,103.63, up 42.74% from ¥189,734,884.06 year-on-year[72] - Diluted earnings per share rose by 44.00% to ¥0.3495 from ¥0.2427 year-on-year[72] Operating Costs and Expenses - The company's operating costs rose by 41.52% to CNY 158.66 million, primarily due to increased sales volume and rising product costs[25] - The company reported a significant increase in management expenses, which rose by 39.32% to CNY 38.47 million due to increased share-based payment expenses[25] - Operating costs for the period were ¥421,939,785.99, compared to ¥350,485,573.54 in the previous year, indicating a rise in operational expenses[62] Cash Flow and Investments - Net cash flow from operating activities improved significantly to CNY 507,095,246.43, up from CNY 239,264,872.20, marking a growth of approximately 111.2%[43] - The company reported a net loss in investment activities of CNY 839,267,821.10, worsening from a loss of CNY 27,396,284.25 in the previous period[43] - The cash flow from investment activities showed a net outflow of ¥839,267,821.10, a significant increase compared to the previous year[50] - The cash flow from financing activities resulted in a net outflow of ¥93,208,529.89, reflecting payments for share repurchases and bank loan repayments[50] Assets and Liabilities - The total assets of the company increased to CNY 5,853,639,782.63, up from CNY 5,543,301,641.00 at the beginning of the period, representing a growth of approximately 5.58%[34] - Total liabilities increased to CNY 2,620,018,537.46, up from CNY 2,390,427,115.63, representing a growth of approximately 9.6% year-over-year[37] - Total owner's equity rose to CNY 3,233,621,245.17, compared to CNY 3,152,874,525.37, reflecting an increase of about 2.5%[38] - The total liabilities to equity ratio stands at approximately 81.1%, indicating a slight increase from the previous ratio[38] Share Repurchase and Equity - The company repurchased a total of 24,242,904 shares, accounting for 3.00% of the total share capital, with a total repurchase amount of CNY 499,996,900[32] - The company’s retained earnings grew to CNY 2,288,684,926.85, up from CNY 2,003,918,783.75, showing an increase of about 14.2%[38] - Equity attributable to shareholders of the listed company was ¥3,229,059,708.62, up 2.59% from ¥3,147,475,025.76 at the end of the previous year[72] Future Outlook - The company plans to continue its market expansion and product development strategies, focusing on innovative technologies and new product launches in the upcoming quarters[33] - The company has implemented organizational restructuring and management process optimization to enhance operational efficiency[10]